vs
Side-by-side financial comparison of Energy Services of America CORP (ESOA) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $114.1M, roughly 1.6× Energy Services of America CORP). On growth, Energy Services of America CORP posted the faster year-over-year revenue change (13.4% vs 5.0%). Over the past eight quarters, Energy Services of America CORP's revenue compounded faster (26.7% CAGR vs -0.2%).
Superior Energy Services is an American oil services company that operates as a holding company for a portfolio of oilfield equipment rentals and well oil and gas services brands.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
ESOA vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $114.1M | $177.4M |
| Net Profit | — | $2.9M |
| Gross Margin | 12.3% | — |
| Operating Margin | 4.3% | 3.9% |
| Net Margin | — | 1.6% |
| Revenue YoY | 13.4% | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.16 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $114.1M | $196.9M | ||
| Q3 25 | $130.1M | $179.5M | ||
| Q2 25 | $103.6M | $181.1M | ||
| Q1 25 | $76.7M | $168.9M | ||
| Q4 24 | $100.6M | $187.3M | ||
| Q3 24 | $104.7M | $168.6M | ||
| Q2 24 | $85.9M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $5.4M | ||
| Q2 25 | — | $-4.8M | ||
| Q1 25 | — | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-143.5M | ||
| Q2 24 | — | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 12.3% | 79.5% | ||
| Q3 25 | 12.6% | 80.9% | ||
| Q2 25 | 11.6% | 77.4% | ||
| Q1 25 | 0.1% | 79.7% | ||
| Q4 24 | 10.2% | 78.7% | ||
| Q3 24 | 16.8% | 76.9% | ||
| Q2 24 | 17.8% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 4.3% | 1.2% | ||
| Q3 25 | 5.8% | 3.5% | ||
| Q2 25 | 3.1% | 4.7% | ||
| Q1 25 | -10.6% | 1.2% | ||
| Q4 24 | 1.6% | 13.2% | ||
| Q3 24 | 8.4% | -82.8% | ||
| Q2 24 | 9.9% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 3.0% | ||
| Q2 25 | — | -2.7% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -85.1% | ||
| Q2 24 | — | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.16 | $0.05 | ||
| Q3 25 | $0.26 | $0.12 | ||
| Q2 25 | $0.12 | $-0.11 | ||
| Q1 25 | $-0.41 | $0.10 | ||
| Q4 24 | $0.05 | $0.38 | ||
| Q3 24 | $0.40 | $-3.11 | ||
| Q2 24 | $1.06 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.7M | $144.3M |
| Total DebtLower is stronger | $62.0M | — |
| Stockholders' EquityBook value | $60.6M | $653.9M |
| Total Assets | $201.0M | $1.2B |
| Debt / EquityLower = less leverage | 1.02× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $16.7M | $238.4M | ||
| Q3 25 | $12.2M | $246.3M | ||
| Q2 25 | $15.3M | $445.9M | ||
| Q1 25 | $9.9M | $493.6M | ||
| Q4 24 | $20.3M | $484.6M | ||
| Q3 24 | $12.9M | $453.8M | ||
| Q2 24 | $14.5M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $62.0M | $372.2M | ||
| Q3 25 | $72.2M | $376.7M | ||
| Q2 25 | $59.1M | $580.5M | ||
| Q1 25 | $50.7M | $583.4M | ||
| Q4 24 | $59.6M | $585.3M | ||
| Q3 24 | $33.9M | — | ||
| Q2 24 | $31.9M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $60.6M | $693.1M | ||
| Q3 25 | $59.2M | $727.2M | ||
| Q2 25 | $54.4M | $757.8M | ||
| Q1 25 | $53.7M | $798.5M | ||
| Q4 24 | $61.0M | $778.3M | ||
| Q3 24 | $58.7M | $749.6M | ||
| Q2 24 | $52.0M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $201.0M | $1.3B | ||
| Q3 25 | $215.2M | $1.3B | ||
| Q2 25 | $189.1M | $1.5B | ||
| Q1 25 | $170.2M | $1.6B | ||
| Q4 24 | $192.1M | $1.6B | ||
| Q3 24 | $158.2M | $1.5B | ||
| Q2 24 | $148.8M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 1.02× | 0.54× | ||
| Q3 25 | 1.22× | 0.52× | ||
| Q2 25 | 1.09× | 0.77× | ||
| Q1 25 | 0.94× | 0.73× | ||
| Q4 24 | 0.98× | 0.75× | ||
| Q3 24 | 0.58× | — | ||
| Q2 24 | 0.61× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.8M | — |
| Free Cash FlowOCF − Capex | $16.8M | — |
| FCF MarginFCF / Revenue | 14.7% | — |
| Capex IntensityCapex / Revenue | 1.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $3.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $18.8M | $43.7M | ||
| Q3 25 | $-9.3M | $60.8M | ||
| Q2 25 | $3.4M | $12.0M | ||
| Q1 25 | $1.1M | $35.5M | ||
| Q4 24 | $8.9M | $33.1M | ||
| Q3 24 | $-847.5K | $53.9M | ||
| Q2 24 | $19.3M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $16.8M | $43.5M | ||
| Q3 25 | $-12.0M | $57.0M | ||
| Q2 25 | $-582.0K | $9.3M | ||
| Q1 25 | $-1.1M | $26.9M | ||
| Q4 24 | $6.0M | $31.0M | ||
| Q3 24 | $-2.9M | $49.8M | ||
| Q2 24 | $16.3M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 14.7% | 22.1% | ||
| Q3 25 | -9.3% | 31.7% | ||
| Q2 25 | -0.6% | 5.1% | ||
| Q1 25 | -1.4% | 15.9% | ||
| Q4 24 | 5.9% | 16.6% | ||
| Q3 24 | -2.8% | 29.6% | ||
| Q2 24 | 18.9% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 1.8% | 0.1% | ||
| Q3 25 | 2.1% | 2.2% | ||
| Q2 25 | 3.9% | 1.5% | ||
| Q1 25 | 2.9% | 5.1% | ||
| Q4 24 | 2.9% | 1.1% | ||
| Q3 24 | 2.0% | 2.4% | ||
| Q2 24 | 3.6% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESOA
| Electricals Mechanical And General | $49.4M | 43% |
| Gas And Petroleum Transmission | $24.1M | 21% |
| Cost Plus And TM Contracts | $23.3M | 20% |
| Transferred At Point In Time | $17.9M | 16% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
